# Safety and Efficacy Study in Recurrent or Progressive Grade III or IV IDH1 Mutated Glioma

Source: https://onco.cc/trials/nct02704858/  
OnCo record `nct02704858` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1/2 trial of Perillyl alcohol in glioma & glioblastoma, run by Neonc Technologies, Inc., active and no longer recruiting.

## Summary

Safety and Efficacy Study in Recurrent or Progressive Grade III or IV IDH1 Mutated Glioma is a phase 1/2 interventional study registered as NCT02704858 by Neonc Technologies, Inc., with 49 participants enrolled, started 2017-08-01 and due to reach its primary completion in 2026-11-30. Interventions recorded: Perillyl alcohol.

## Fields

- Kind: Trial
- Status: active
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT02704858
- Phase: 1/2
- Setting: An Open-Label, Phase 1/2A Dose Escalation Study of Safety and Efficacy of NEO100 in Recurrent or Progressive Grade III or Grade IV Gliomas With IDH1 Mutation
- Sponsor: Neonc Technologies, Inc.
- Enrolled: 49

## Sources

- ClinicalTrials.gov NCT02704858: https://clinicaltrials.gov/study/NCT02704858

## Connected records

- cancers: [Glioma & glioblastoma](https://onco.cc/cancers/glioblastoma/)
- companies: [Neonc Technologies](https://onco.cc/companies/neonc-technologies/)

---
JSON: https://onco.cc/api/v1/entities/nct02704858.json